Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.09 SEK | 6.03% |
| 2022 | -1.16 SEK | -14.85% |
| 2021 | -1.01 SEK | 0.98% |
| 2020 | -1.02 SEK | -25.93% |
| 2019 | -0.81 SEK | 10.99% |
| 2018 | -0.91 SEK | -40.0% |
| 2017 | -0.65 SEK | 29.35% |
| 2016 | -0.92 SEK | -24.32% |
| 2015 | -0.74 SEK | -196.0% |
| 2014 | -0.25 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.04 SEK | -112.98% |
| 2024 Q1 | -0.02 SEK | 96.0% |
| 2023 Q3 | -0.11 SEK | 31.25% |
| 2023 Q4 | -0.52 SEK | -372.73% |
| 2023 FY | - SEK | 6.03% |
| 2023 Q1 | -0.14 SEK | 60.0% |
| 2023 Q2 | -0.16 SEK | -14.29% |
| 2022 Q2 | -0.32 SEK | -33.33% |
| 2022 FY | - SEK | -14.85% |
| 2022 Q4 | -0.35 SEK | -45.83% |
| 2022 Q3 | -0.24 SEK | 25.0% |
| 2022 Q1 | -0.24 SEK | 35.14% |
| 2021 Q2 | -0.33 SEK | -13.79% |
| 2021 Q1 | -0.29 SEK | 14.71% |
| 2021 FY | - SEK | 0.98% |
| 2021 Q4 | -0.37 SEK | -105.56% |
| 2021 Q3 | -0.18 SEK | 45.45% |
| 2020 FY | - SEK | -25.93% |
| 2020 Q1 | -0.20 SEK | 37.5% |
| 2020 Q3 | -0.18 SEK | 41.94% |
| 2020 Q4 | -0.34 SEK | -88.89% |
| 2020 Q2 | -0.31 SEK | -55.0% |
| 2019 Q2 | -0.13 SEK | 38.1% |
| 2019 Q1 | -0.21 SEK | 41.67% |
| 2019 FY | - SEK | 10.99% |
| 2019 Q3 | -0.15 SEK | -15.38% |
| 2019 Q4 | -0.32 SEK | -113.33% |
| 2018 Q3 | -0.17 SEK | 15.0% |
| 2018 Q1 | -0.19 SEK | 20.83% |
| 2018 Q2 | -0.20 SEK | -5.26% |
| 2018 Q4 | -0.36 SEK | -111.76% |
| 2018 FY | - SEK | -40.0% |
| 2017 Q2 | -0.27 SEK | -17.39% |
| 2017 FY | - SEK | 29.35% |
| 2017 Q4 | -0.24 SEK | -26.32% |
| 2017 Q3 | -0.19 SEK | 29.63% |
| 2017 Q1 | -0.23 SEK | 0.0% |
| 2016 Q1 | -0.25 SEK | -4.17% |
| 2016 Q2 | -0.22 SEK | 12.0% |
| 2016 FY | - SEK | -24.32% |
| 2016 Q4 | -0.23 SEK | -53.33% |
| 2016 Q3 | -0.15 SEK | 31.82% |
| 2015 Q3 | -0.18 SEK | -20.0% |
| 2015 Q1 | -0.06 SEK | -468.48% |
| 2015 Q2 | -0.15 SEK | -146.71% |
| 2015 Q4 | -0.24 SEK | -33.33% |
| 2015 FY | - SEK | -196.0% |
| 2014 Q3 | -0.06 SEK | -30.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q2 | -0.04 SEK | 0.0% |
| 2014 Q4 | 0.02 SEK | 128.85% |
| 2014 Q1 | -0.04 SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -581.25% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | -81.667% |
| BioGaia AB (publ) | 3.62 SEK | 130.11% |
| Enzymatica AB (publ) | -0.28 SEK | -289.286% |
| Enorama Pharma AB (publ) | -1.61 SEK | 32.298% |
| Gabather AB (publ) | -0.65 SEK | -67.692% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | -202.778% |
| Moberg Pharma AB (publ) | -1.33 SEK | 18.045% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | -51.389% |
| ODI Pharma AB | 0.02 SEK | 4758.12% |
| Orexo AB (publ) | -3.73 SEK | 70.777% |
| Probi AB (publ) | 1.48 SEK | 173.649% |
| Swedencare AB (publ) | 0.37 SEK | 394.595% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 114.592% |
| Toleranzia AB | -0.06 SEK | -1846.429% |
| Vivesto AB | -0.74 SEK | -47.297% |